Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study.
Quick navigation
Link to full study
http://www.ncbi.nlm.nih.gov/pubmed/15655130
Conclusion of this study
Administration of irbesartan and/or lipoic acid to patients with the metabolic syndrome improves endothelial function and reduces proinflammatory markers, factors that are implicated in the pathogenesis of atherosclerosis.
Supplements analyzed in this study
Health conditions analyzed in this study
Functions related to this study
Body systems related to this study